The miR-182-5p/NRF2 Axis and Inflammation Across Glycemic States in Type 2 Diabetes Mellitus: An Integrated Clinical and Molecular Study
DOI:
https://doi.org/10.55544/sjmars.5.4.3Keywords:
type 2 diabetes, ferroptosis, NRF2, miR-182-5p, ferritin, IL-6, TNF-α, oxidative stressAbstract
Background: Type 2 Diabetes Mellitus (T2DM) is becoming a worldwide health condition. High blood glucose for a prolonged period of time increases oxidative stress. Ferroptosis is a cell death mediated by iron. May be associated with iron overload, oxidative stress and tissue damage in diabetes. MicroRNA miR-182-5p has the ability to inhibit antioxidant regulator NRF2.
Objectives: This study quantified the expression of miR-182-5p and NRF2 gene. It also quantified serum ferritin, interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-α). Their goal was to evaluate the changes of these markers with worsening glycemic control.
Materials and methods: 180 adults classified into 3 equal groups. The groups comprised healthy controls, newly diagnosed T2DM, and poorly controlled T2DM. The expression of the genes was determined by the RT-qPCR method and calculated using the 2-ΔΔCt method. ANOVA, Tukey HSD, correlation, ROC and regression analysis was used to analyze the data.
Results: Patients with newly diagnosed T2DM and poorly controlled T2DM showed a progressive rise in miR-182-5p expression, ferritin, IL-6 and TNF-α levels with a significant decrease in NRF2 expression (all p < 0.001). HbA1c was well correlated with all biomarkers with an inverse correlation with NRF2. An inverse relationship between the expression of miR-182-5p and NRF2 was linked to poor glycemic status. Receiver operating characteristic analysis revealed good diagnostic values for miR-182-5p (AUC = 0.991), TNF-α (0.989), IL-6 (0.980), NRF2 (0.979), and ferritin (0.973). The independent predictive value of miR-182-5p, ferritin, IL-6, and insulin for HbA1c was established by multivariable analysis; combined biomarker analysis was able to accurately discriminate poorly controlled from newly diagnosed T2DM.
Conclusions: A progressive dysregulation of miR-182-5p/NRF2 axis is closely linked to the deterioration of glycemic control, inflammation and iron metabolism in type 2 diabetes mellitus. These biomarkers could be useful for disease stratification and as potential targets for future therapies and risk assessment.
References
[1] Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi:10.1016/j.diabres.2021.109119.
[2] Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes – global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107–11. doi:10.2991/jegh.k.191028.001.
[3] Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–25. doi:10.2337/diabetes.54.6.1615.
[4] Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–70. doi:10.1161/CIRCRESAHA.110.223545.
[5] Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72. doi:10.1016/j.cell.2012.03.042.
[6] Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1–2):317–31. doi:10.1016/j.cell.2013.12.010.
[7] Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273–85. doi:10.1016/j.cell.2017.09.021.
[8] Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266–82. doi:10.1038/s41580-020-00324-8.
[9] Miao R, Fang X, Zhang Y, Wei J, Zhang Y, Tian J. Iron metabolism and ferroptosis in type 2 diabetes mellitus and complications: mechanisms and therapeutic opportunities. Cell Death Dis. 2023;14(3):186. doi:10.1038/s41419-023-05708-0.
[10] Elumalai S, Karunakaran U, Moon JS, Won KC. Ferroptosis signaling in pancreatic β-cells: novel insights and therapeutic targeting. Int J Mol Sci. 2022;23(22):13679. doi:10.3390/ijms232213679.
[11] David JA, Rifkin WJ, Rabbani PS, Ceradini DJ. The Nrf2/Keap1/ARE pathway and oxidative stress as a therapeutic target in type II diabetes mellitus. J Diabetes Res. 2017;2017:4826724. doi:10.1155/2017/4826724.
[12] Baird L, Yamamoto M. The molecular mechanisms regulating the KEAP1-NRF2 pathway. Mol Cell Biol. 2020;40(13):e00099-20. doi:10.1128/MCB.00099-20.
[13] Bhakkiyalakshmi E, Sireesh D, Rajaguru P, Paulmurugan R, Ramkumar KM. The emerging role of redox-sensitive Nrf2–Keap1 pathway in diabetes. Pharmacol Res. 2015;91:104–14. doi:10.1016/j.phrs.2014.10.004.
[14] Qadir MMF, Klein D, Álvarez-Cubela S, Domínguez-Bendala J, Pastori RL. The role of microRNAs in diabetes-related oxidative stress. Int J Mol Sci. 2019;20(21):5423. doi:10.3390/ijms20215423.
[15] Liu J, Li Q, Yang Y, Ma L. Iron metabolism and type 2 diabetes mellitus: a meta-analysis and systematic review. J Diabetes Investig. 2020;11(4):946–55. doi:10.1111/jdi.13216.
[16] Kunutsor SK, Apekey TA, Walley J, Kain K. Ferritin levels and risk of type 2 diabetes mellitus: an updated systematic review and meta-analysis of prospective evidence. Diabetes Metab Res Rev. 2013;29(4):308–18. doi:10.1002/dmrr.2394.
[17] Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–34. doi:10.1001/jama.286.3.327.
[18] Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98–107. doi:10.1038/nri2925.
[19] Sireesh D, Dhamodharan U, Ezhilarasi K, Vijay V, Ramkumar KM. Association of NF-E2 related factor 2 (Nrf2) and inflammatory cytokines in recent onset type 2 diabetes mellitus. Sci Rep. 2018;8(1):5126. doi:10.1038/s41598-018-22913-6.
[20] Golpour P, Nourbakhsh M, Mazaherioun M, Janani L, Nourbakhsh M, Yaghmaei P. Improvement of NRF2 gene expression and antioxidant status in patients with type 2 diabetes mellitus after supplementation with omega-3 polyunsaturated fatty acids: a double-blind randomised placebo-controlled clinical trial. Diabetes Res Clin Pract. 2020;162:108120. doi:10.1016/j.diabres.2020.108120.
[21] Scherbak NN, Kruse R, Nyström T, Jendle J. Glimepiride compared to liraglutide increases plasma levels of miR-206, miR-182-5p, and miR-766-3p in type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab J. 2023;47(5):668–81. doi:10.4093/dmj.2022.0342.
[22] Weale CJ, Matshazi DM, Davids SFG, Raghubeer S, Erasmus RT, Kengne AP, et al. Circulating miR-30a-5p and miR-182-5p in prediabetes and screen-detected diabetes mellitus. Diabetes Metab Syndr Obes. 2020;13:5037–47. doi:10.2147/DMSO.S286081.
[23] Krause C, Britsemmer JH, Bernecker M, Molenaar A, Taege N, Lopez-Alcantara N, et al. Liver microRNA transcriptome reveals miR-182 as link between type 2 diabetes and fatty liver disease in obesity. eLife. 2024;13:e92075. doi:10.7554/eLife.92075.
[24] Al Argan R, Alkhafaji D, Al Elq A, Albaker W, Elamin Y, Alwaheed A, et al. The association between serum ferritin and bilirubin with glycemic control among patients with type 2 diabetes mellitus. J Med Life. 2023;16(11):1670–7. doi:10.25122/jml-2023-0136.
[25] Tummalacharla SC, Pavuluri P, Maram SR, Vadakedath S, Kondu D, Karpay S, et al. Serum activities of ferritin among controlled and uncontrolled type 2 diabetes mellitus patients. Cureus. 2022;14(5):e25155. doi:10.7759/cureus.25155.
[26] Liu BW, Xuan XM, Liu JR, Li FN, Yin FZ. The relationship between serum ferritin and insulin resistance in different glucose metabolism in nonobese Han adults. Int J Endocrinol. 2015;2015:642194. doi:10.1155/2015/642194.
[27] Jiang L, Wang K, Lo K, Zhong Y, Yang A, Fang X, et al. Sex-specific association of circulating ferritin level and risk of type 2 diabetes: a dose-response meta-analysis of prospective studies. J Clin Endocrinol Metab. 2019;104(10):4539–51. doi:10.1210/jc.2019-00495.
[28] Arab Sadeghabadi Z, Abbasalipourkabir R, Mohseni R, Ziamajidi N. Investigation of oxidative stress markers and antioxidant enzymes activity in newly diagnosed type 2 diabetes patients and healthy subjects, association with IL-6 level. J Diabetes Metab Disord. 2019;18(2):437–43. doi:10.1007/s40200-019-00437-8.
[29] Bashir H, Bhat SA, Majid S, Hamid R, Koul RK, Rehman MU, et al. Role of inflammatory mediators (TNF-α, IL-6, CRP), biochemical and hematological parameters in type 2 diabetes mellitus patients of Kashmir, India. Med J Islam Repub Iran. 2020;34:5. doi:10.47176/mjiri.34.5.
[30] Phosat C, Panprathip P, Chumpathat N, Prangthip P, Chantratita N, Soonthornworasiri N, et al. Elevated C-reactive protein, interleukin 6, tumor necrosis factor alpha and glycemic load associated with type 2 diabetes mellitus in rural Thais: a cross-sectional study. BMC Endocr Disord. 2017;17(1):44. doi:10.1186/s12902-017-0189-z.
[31] Hashmi MRUI, Sadiq S, Hashmi SN, Zubair R, Shafique H, Afsar T, et al. Correlation of TNF-α and IL-6 expression with vitamin D levels in insulin-resistant type 2 diabetes mellitus patients: exploring the role of vitamin D in inflammation and disease pathogenesis. BMC Immunol. 2025;26(1):68. doi:10.1186/s12865-025-00754-z.
[32] Al-Hilu M. The role of inflammation IL-6, TNF-α in type-2 diabetes mellitus. Al-Kufa Univ J Biol. 2025;17(2):89–97. Available from:
[33] https://journal.uokufa.edu.iq/index.php/ajb/article/view/19615.
[34] Akash MSH, Rehman K, Liaqat A. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2018;119(1):105–10. doi:10.1002/jcb.26174.
[35] Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474–89. doi:10.1016/S2213-8587(23)00119-5.
[36] Al-Rifai RH, Abdo NM, Paulo MS, Saha S, Ahmed LA. Prevalence of gestational diabetes mellitus in the Middle East and North Africa, 2000–2019: a systematic review, meta-analysis, and meta-regression. Front Endocrinol. 2021
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Stallion Journal for Multidisciplinary Associated Research Studies
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
10.55544/sjmars
editor@sjmars.com | 
+91-8874396939
